ZimVie (NASDAQ:ZIMV) Releases FY 2024 Earnings Guidance

ZimVie (NASDAQ:ZIMV) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 0.550-0.700 for the period, compared to the consensus estimate of 0.100. The company issued revenue guidance of $450.0 million-$460.0 million, compared to the consensus revenue estimate of $454.1 million.

ZimVie Trading Down 4.2 %

Shares of ZIMV traded down $0.67 during trading hours on Wednesday, hitting $15.38. 332,335 shares of the stock traded hands, compared to its average volume of 335,529. The company has a current ratio of 2.78, a quick ratio of 2.32 and a debt-to-equity ratio of 1.26. ZimVie has a 1-year low of $6.52 and a 1-year high of $20.91. The firm has a market capitalization of $418.64 million, a PE ratio of -1.04 and a beta of 2.17. The business has a fifty day moving average of $16.48 and a 200-day moving average of $14.99.

ZimVie (NASDAQ:ZIMV) last issued its quarterly earnings results on Wednesday, February 28th. The company reported $0.10 earnings per share (EPS) for the quarter. ZimVie had a positive return on equity of 2.44% and a negative net margin of 51.33%. The business had revenue of $113.07 million for the quarter.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Needham & Company LLC reissued a hold rating on shares of ZimVie in a research note on Thursday, April 11th. Barclays increased their target price on ZimVie from $13.00 to $16.00 and gave the company an underweight rating in a research note on Tuesday, March 5th.

About ZimVie

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.